Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Date:12/12/2012

ycemic control has been demonstrated to reduce the onset and progression of these complications.

About Janssen Research & Development, LLC

Janssen Research & Development, LLC is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research & Development is leveraging a combination of internal and external innovation to discover and develop novel medicines and solutions in five distinct therapeutic areas: Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research & Development, LLC visit www.janssenrnd.com.  

Janssen Research & Development is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to address serious unmet medical needs around the world.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health ca
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... CRY ), a leading medical device and tissue ... today its results for the second quarter and first ... Chairman, President and Chief Executive Officer, said, "During the ... with solid progress on several of our top organizational ... a direct sales model in France, advancing our strategic ...
(Date:7/28/2015)... Minn. , July 28, 2015 ANI ... the Company plans to release its second quarter and ... before the opening of the U.S. financial markets. The ... Relations section of the Company,s website, www.anipharmaceuticals.com . ... Chief Executive Officer, and Charlotte C. Arnold , ...
(Date:7/28/2015)... Oncology, Inc. (OTC: CSBR), engaged in the development of ... and use of oncology drugs, today announced its financial ... Fourth Quarter and Recent Business Highlights: , ... period result , Procured a quarterly record high ... Champions Oncology CEO, stated, "The end of fiscal 2015 ...
Breaking Medicine Technology:CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... According to ... able to stop the cycle of addiction in lab mice. The study involving isradipine ... for the new prospect of helping their clients overcome drug and alcohol addictions. The ...
(Date:7/28/2015)... ... July 28, 2015 , ... Bipolar disorder is often associated with mood swings ... times a year. The World Health Organization (WHO) has reported that bipolar disorder affects ... Health reveals that the United States has the highest lifetime rate of bipolar disorder ...
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard ... authorized the Company, from time to time and depending on market conditions, to ... to $25 million. Repurchases will be made in open market or privately negotiated ...
(Date:7/28/2015)... ... 28, 2015 , ... Fertility specialist Dr. Lisa Hasty of Atlanta ... Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been recognized ... peers in the metro area as one of the most respected doctors in Reproductive ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom are missed ... the identification of individuals with active yet undetected sub-clinical disease, who are at ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... (HealthDay News) -- In men who,ve had their prostate surgically ... a rise in blood levels of prostate specific antigen (PSA) ... So finds a new study slated to be presented Monday ... in Washington, D.C. The study included 321 smokers ...
... --,More than half of those who develop Alzheimer,s disease before ... signs of the disease are symptoms other than memory problems, ... of 40 people from Barcelona who were found to have ... the age at which the symptoms began, as well as ...
... of workshops held by the Institute of Medicine explored ... to harness the full potential of new digital technologies ... efficiency and apply knowledge to real-time care decisions. , ... for Continuous Improvement in Health and Health Care recaps ...
... strong commitment to medical and health research and recognize ... and the nation,s economy, according to a new statewide ... Ohio Medical University (NEOMED). A strong majority ... important42% say very importantto the state,s economy. Eight in ...
... is the fourth-most-common cancer in men and one of ... death. After initial diagnosis and surgery, patients must return ... time-consuming and uncomfortable bladder scan. Tumors recur in more ... Washington are proposing a more automated approach that could ...
... Researchers at Sandia National Laboratories have developed a ... about exactly how and why a cell,s defenses ... successfully fending off others like E.coli. The approach ... which could open doors to new diagnostic, prevention ...
Cached Medicine News:Health News:Research Shows Early Onset Alzheimer's Disease Sometimes Missed 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 3Health News:Digital imaging software to create a 'Google Earth' view of the bladder 2Health News:Digital imaging software to create a 'Google Earth' view of the bladder 3Health News:Sandia Labs unlocks secrets of plague with stunning new imaging techniques 2Health News:Sandia Labs unlocks secrets of plague with stunning new imaging techniques 3
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades allow intraocular manipulation without metal to metal contact. 16 mm lifting wings. Dull finish....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Medicine Products: